burger

A pharmaceutical company
specialising in biological
medicinal products

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€362M in turnover

in 2020

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

All news

2:38

Part 2 : the new Momentum

3:32

Part 1: three years of LFB transformation

2:34

The LFB 2021 coporate Brochure in video

2:33

LFB Arras plant under construction in October 2020 in video

All videos

Three years of LFB transformation - Part 3 The LFB's values

Three years of LFB transformation - Part 2 The New Momentum
ISTH

LFB is present at the ISTH international congress

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès
Découvrez la nouvelle Brochure du LFB

Take a look at the new LFB corporate brochure!

LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19

LFB announces FDA approval of SEVENFACT®, a recombinant coagulation Factor VIIa

2:38

Part 2 : the new Momentum

there is 2 months

3:32

Part 1: three years of LFB transformation

there is 3 months

2:34

The LFB 2021 coporate Brochure in video

there is 6 months

2:33

LFB Arras plant under construction in October 2020 in video

there is 8 months